Fig. 1
From: Design considerations of an IL13Rα2 antibody–drug conjugate for diffuse intrinsic pontine glioma
Gene expression in DIPG. High-throughput RNA sequencing of 33 DIPG tumor samples vs. 20 normal brain samples across two cohorts. a IL13Rα2 tumor expression versus normal expression (p < 0.01). b Tumor-normal expression ratios of IL13Rα2 and IL13Rα1 across patient-matched DIPG samples (p < 0.01). c IL13Rα2 tumor expression versus normal expression (p < 0.0001). d Expression of IL13Rα2 in DIPG and GBM cell models (HEK293 as positive control) determined by immunoblotting. SF-8628, CHLA-200, DIPG-6, and DIPG-17 are IL13Rα2-high models, while DIPG-24 is IL13Rα2-low